Literature DB >> 17483121

Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

Hugh A Barton1, Weihsueh A Chiu, R Woodrow Setzer, Melvin E Andersen, A John Bailer, Frédéric Y Bois, Robert S Dewoskin, Sean Hays, Gunnar Johanson, Nancy Jones, George Loizou, Robert C Macphail, Christopher J Portier, Martin Spendiff, Yu-Mei Tan.   

Abstract

Physiologically based pharmacokinetic (PBPK) models are used in mode-of-action based risk and safety assessments to estimate internal dosimetry in animals and humans. When used in risk assessment, these models can provide a basis for extrapolating between species, doses, and exposure routes or for justifying nondefault values for uncertainty factors. Characterization of uncertainty and variability is increasingly recognized as important for risk assessment; this represents a continuing challenge for both PBPK modelers and users. Current practices show significant progress in specifying deterministic biological models and nondeterministic (often statistical) models, estimating parameters using diverse data sets from multiple sources, using them to make predictions, and characterizing uncertainty and variability of model parameters and predictions. The International Workshop on Uncertainty and Variability in PBPK Models, held 31 Oct-2 Nov 2006, identified the state-of-the-science, needed changes in practice and implementation, and research priorities. For the short term, these include (1) multidisciplinary teams to integrate deterministic and nondeterministic/statistical models; (2) broader use of sensitivity analyses, including for structural and global (rather than local) parameter changes; and (3) enhanced transparency and reproducibility through improved documentation of model structure(s), parameter values, sensitivity and other analyses, and supporting, discrepant, or excluded data. Longer-term needs include (1) theoretical and practical methodological improvements for nondeterministic/statistical modeling; (2) better methods for evaluating alternative model structures; (3) peer-reviewed databases of parameters and covariates, and their distributions; (4) expanded coverage of PBPK models across chemicals with different properties; and (5) training and reference materials, such as cases studies, bibliographies/glossaries, model repositories, and enhanced software. The multidisciplinary dialogue initiated by this Workshop will foster the collaboration, research, data collection, and training necessary to make characterizing uncertainty and variability a standard practice in PBPK modeling and risk assessment.

Entities:  

Mesh:

Year:  2007        PMID: 17483121     DOI: 10.1093/toxsci/kfm100

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  29 in total

1.  In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Authors:  Olavi Pelkonen; Miia Turpeinen; Hannu Raunio
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

Review 2.  Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.

Authors:  Clara Hartmanshenn; Megerle Scherholz; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

Review 3.  In vitro to in vivo extrapolation for high throughput prioritization and decision making.

Authors:  Shannon M Bell; Xiaoqing Chang; John F Wambaugh; David G Allen; Mike Bartels; Kim L R Brouwer; Warren M Casey; Neepa Choksi; Stephen S Ferguson; Grazyna Fraczkiewicz; Annie M Jarabek; Alice Ke; Annie Lumen; Scott G Lynn; Alicia Paini; Paul S Price; Caroline Ring; Ted W Simon; Nisha S Sipes; Catherine S Sprankle; Judy Strickland; John Troutman; Barbara A Wetmore; Nicole C Kleinstreuer
Journal:  Toxicol In Vitro       Date:  2017-12-05       Impact factor: 3.500

4.  A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models.

Authors:  Megerle L Scherholz; James Forder; Ioannis P Androulakis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-08       Impact factor: 2.745

5.  Assessing Toxicokinetic Uncertainty and Variability in Risk Prioritization.

Authors:  John F Wambaugh; Barbara A Wetmore; Caroline L Ring; Chantel I Nicolas; Robert G Pearce; Gregory S Honda; Roger Dinallo; Derek Angus; Jon Gilbert; Teresa Sierra; Akshay Badrinarayanan; Bradley Snodgrass; Adam Brockman; Chris Strock; R Woodrow Setzer; Russell S Thomas
Journal:  Toxicol Sci       Date:  2019-12-01       Impact factor: 4.849

6.  Evaluation and calibration of high-throughput predictions of chemical distribution to tissues.

Authors:  Robert G Pearce; R Woodrow Setzer; Jimena L Davis; John F Wambaugh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-14       Impact factor: 2.745

7.  Identifiability of PBPK models with applications to dimethylarsinic acid exposure.

Authors:  Ramon I Garcia; Joseph G Ibrahim; John F Wambaugh; Elaina M Kenyon; R Woodrow Setzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-21       Impact factor: 2.745

8.  A HIERARCHICAL FUNCTIONAL DATA ANALYTIC APPROACH FOR ANALYZING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS.

Authors:  Siddhartha Mandal; Pranab K Sen; Shyamal D Peddada
Journal:  Environmetrics       Date:  2013-05-01       Impact factor: 1.900

9.  Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.

Authors:  John F Wambaugh; Hugh A Barton; R Woodrow Setzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-08       Impact factor: 2.745

Review 10.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

Authors:  Yu-Mei Tan; Rachel R Worley; Jeremy A Leonard; Jeffrey W Fisher
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.